This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Option Care (OPCH) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 18.18% and 0.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Elanco Animal Health Incorporated (ELAN) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 46.15% and 0.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Option Care Health, LifeStance Health, Addus HomeCare and Pennant
by Zacks Equity Research
Option Care Health, LifeStance Health, Addus HomeCare and Pennant have been highlighted in this Industry Outlook article.
4 Stocks to Watch Amid a Challenging Outpatient Home Health Industry
by Zacks Equity Research
Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. OPCH, LFST, ADUS and PNTG are well poised to gain from the prospects.
Option Care (OPCH) Q3 Earnings Match Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 0% and 2.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Option Care (OPCH) Stock Jumps 8.9%: Will It Continue to Soar?
by Zacks Equity Research
Option Care (OPCH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Option Care (OPCH) Misses Q2 Earnings Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of -13.64% and 3.99%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's What Could Help Option Care (OPCH) Maintain Its Recent Price Strength
by Zacks Equity Research
Option Care (OPCH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Option Care (OPCH) Stock Jumps 5.6%: Will It Continue to Soar?
by Zacks Equity Research
Option Care (OPCH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Has Natus Medical (NTUS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Natus Medical (NTUS) and Option Care (OPCH) have performed compared to their sector so far this year.
Here's What Could Help Option Care (OPCH) Maintain Its Recent Price Strength
by Zacks Equity Research
Option Care (OPCH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Option Care (OPCH) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 30.77% and 9.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Encompass Health (EHC) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of 4.30% and 1.17%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Option Care (OPCH) Q4 Earnings Meet Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 0% and 0.80%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Option Care (OPCH) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Option Care (OPCH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Ford Motor and IRobot have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Ford Motor and IRobot have been highlighted as Zacks Bull and Bear of the Day
Omicron Hits Elective MedTechs, 3 Subsectors Likely to Thrive
by Urmimala Biswas
Here we discuss three major subsectors of MedTech and three constituent stocks, OPCH, GMED and OMCL for which the change in the scenario has opened up enormous growth prospects.
Option Care (OPCH) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Option Care (OPCH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Option Care (OPCH) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 11.11% and 1.01%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Buy Stocks for November 3rd
by Zacks Equity Research
CNX, DOW, SNDR, HLIT, and OPCH have been added to the Zacks Rank #1 (Strong Buy) List on November 3, 2021.
Option Care (OPCH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Option Care (OPCH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 High-Potential MedTech Stocks With More Than 50% Growth YTD
by Riya Anand
Stocks like West Pharmaceuticals Services (WST), Maravai LifeSciences (MRVI) and Option Care Health (OPCH) have gained stupendously year to date.
Option Care (OPCH) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Option Care (OPCH) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Top Ranked Momentum Stocks to Buy for September 14th
by Zacks Equity Research
RRC, OPCH, CNQ, and ARES made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 14, 2021.
What Makes Option Care (OPCH) a Good Fit for "Trend Investing"
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Option Care (OPCH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.